Truman Boyes

I make things work. Optimist. All opinions my own. Former: MLB, Bloomberg, Juniper, Pilot, early ISPs. trumanboyes.eth ; neurology, ALS, biohacking, AI, finance

[Truman Boyes @trumanboyes]

The tech community is extremely connected and small. Make friends! There are so many great conversations waiting to happen.

[Truman Boyes @trumanboyes]

5/ For everyone fighting ALS: This is why we track the science relentlessly. Potential to meaningfully slow progression by hitting TDP-43 head-on. Researchers, patients, advocates—let’s keep the momentum going.
What TDP-43 approaches or other trials are you most optimistic about right now? Drop thoughts below.
#ALS #VTx002 #PIONEERALS #EndALS

[Truman Boyes @trumanboyes]

Thread on VTx-002 / PIONEER-ALS 🧵
1/ Exciting pipeline update for the ALS community: VectorY Therapeutics has recently dosed the first patient in PIONEER-ALS, their Phase I/II trial of VTx-002 at the Sean M. Healey & AMG Center for ALS at Mass General. This marks the first-in-human evaluation of a vectorized antibody targeting pathological TDP-43—the driver in ~97% of cases. Hope on the horizon.

[Truman Boyes @trumanboyes]

4/ Early stage, yes—but smart design with multi-region sites (US, Europe, UK) and strong preclinical rationale. Pairs well with other mechanisms in the pipeline (mitochondrial support like CNM-Au8, survival signals from dazucorilant, etc.). If successful, it could open doors for broader, combination strategies

[Chamath Palihapitiya @chamath]

Here is the first case study of what 8090 can do.

Working with CMS, our Enterprise team decoded a 50yr, 18M repo of COBOL and Assembly that governs billions in healthcare payments. We documented 100,000+ business rules in plain English using Software Factory, each traced to its exact source line.

The people who own Medicare policy can now read how their systems behave and change as they see fit.

Full story in the thread below.

We can do this for any large enterprise who have big, legacy codebases.

[Brian Wallach @bsw5020]

@synapticure is changing the future of ALS research. Reach out to us at [email protected] or 708-507-9691.

[MGH Neurology @MGHNeurology]

A new study by Healey & AMG researchers and collaborators published in @GreenJournal aims to provide the first national framework for projecting the clinical impact of genetic testing and gene-targeted therapies on ALS clinics.

Read more: https://t.co/mUtntRl5Xu  

#ALSResearch

[ALS News Today @alsnewstoday]

A new update highlights progress in a potential nerve-protecting approach that researchers believe could help preserve the nerve fibers damaged in ALS: https://t.co/Y0CcsivFJX

While this research is still in the clinical trial stage, the latest milestone could help move development forward and expand what scientists learn about protecting motor neurons.

Learn what this funding milestone means, how this experimental therapy works, and where the clinical trial stands today.

#ALSResearch #ALSTreatment #ClinicalTrials #ALSNewsToday #Bionews

[Truman Boyes @trumanboyes]

@Neuroscope_mp Thoughts on interaction with ALS / TDP-43 ?

[Truman Boyes @trumanboyes]

This is the future

[Daily Loud @DailyLoud]

Daniel Cressy age 23 becomes the first person in Louisiana to be functionally cured of sickle cell disease through gene therapy

[Daily Loud @DailyLoud]

Daniel Cressy age 23 becomes the first person in Louisiana to be functionally cured of sickle cell disease through gene therapy

[The ALS Association @alsassociation]

Breaking 🚨 Incredible News for the ALS community!!

The House wants to double ALS research funding at the DOD to $80 MILLION! This is all thanks to the lobbying and advocacy efforts from our advocates, volunteers, and ALS Association staff. Together, we submitted 100+ appropriations forms to Congress, lobbied on the Hill, lobbied on Zoom, sent over 10,000 emails to push for more funding and legislative change to increase ALS clinical trials.

We wrote and fought for the legislative language reflected in this funding. It means more clinical trials, more progress, and more hope for every family facing ALS.

But the fight isn't over yet -- on to the Senate!

Contact your Senator and tell them to increase ALS research funding! https://t.co/ImMIcdqdUI

[Truman Boyes @trumanboyes]

Excellent progress on ALS innovation

[Secretary Kennedy @SecKennedy]

Today, HHS launched a historic department-wide effort to strengthen America’s clinical research enterprise and ensure the next generation of medical breakthroughs is developed right here in the United States. Under President Trump’s leadership, we are accelerating innovation, expanding research capacity, and ensuring lifesaving discoveries are made in America.

[Truman Boyes @trumanboyes]

For those tracking the ALS supplement landscape:

7,8-DHF sits at the intersection of BDNF signaling, motor neuron survival, and autophagy enhancement.

It’s not a cure. But as a neuroprotective adjunct while waiting for trials to read out?

The mechanistic case is hard to ignore. 🔬

[Truman Boyes @trumanboyes]

BDNF is one of the most powerful neuroprotective molecules known. It keeps motor neurons alive, drives synaptic plasticity, and slows neurodegeneration.

The problem: it can’t cross the blood-brain barrier.

Enter 7,8-DHF. 🧵

[Truman Boyes @trumanboyes]

Caveats worth knowing:
→ All data is preclinical. Zero human RCTs.
→ Some cell survival studies didn’t replicate
→ Cytotoxic at high concentrations (>20μM in certain systems)
→ A stronger analog (4’-DMA-7,8-DHF) now exists with better TrkB binding affinity

Science in progress.